Cantor Fitzgerald Weighs in on Harpoon Therapeutics, Inc.’s FY2022 Earnings (NASDAQ:HARP)

Harpoon Therapeutics, Inc. (NASDAQ:HARPGet Rating) – Analysts at Cantor Fitzgerald dropped their FY2022 earnings per share (EPS) estimates for shares of Harpoon Therapeutics in a research note issued to investors on Monday, May 16th. Cantor Fitzgerald analyst J. Kim now expects that the company will earn ($2.40) per share for the year, down from their previous forecast of ($2.29). Cantor Fitzgerald has a “Overweight” rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Roth Capital upped their price objective on shares of Harpoon Therapeutics from $14.00 to $18.00 in a report on Tuesday. HC Wainwright cut their price objective on Harpoon Therapeutics from $31.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, March 14th. Piper Sandler cut their price target on Harpoon Therapeutics from $15.00 to $14.00 in a report on Friday, May 13th. SVB Leerink lowered their price objective on shares of Harpoon Therapeutics from $19.00 to $13.00 in a research note on Friday, March 11th. Finally, Robert W. Baird reduced their price target on shares of Harpoon Therapeutics from $35.00 to $14.00 in a report on Monday, March 14th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $15.19.

Shares of HARP opened at $2.84 on Wednesday. The firm’s 50 day moving average price is $3.52 and its 200 day moving average price is $5.20. Harpoon Therapeutics has a twelve month low of $1.73 and a twelve month high of $22.74.

Harpoon Therapeutics (NASDAQ:HARPGet Rating) last posted its quarterly earnings results on Thursday, March 10th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.20). Harpoon Therapeutics had a negative return on equity of 99.99% and a negative net margin of 366.46%. The company had revenue of $4.33 million during the quarter, compared to analyst estimates of $7.03 million.

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in shares of Harpoon Therapeutics by 3.2% during the third quarter. Bank of New York Mellon Corp now owns 47,882 shares of the company’s stock worth $378,000 after purchasing an additional 1,493 shares during the last quarter. Citigroup Inc. raised its position in shares of Harpoon Therapeutics by 50.5% during the 4th quarter. Citigroup Inc. now owns 5,746 shares of the company’s stock valued at $43,000 after acquiring an additional 1,929 shares during the last quarter. IndexIQ Advisors LLC lifted its stake in Harpoon Therapeutics by 11.1% in the third quarter. IndexIQ Advisors LLC now owns 21,491 shares of the company’s stock valued at $170,000 after buying an additional 2,152 shares during the period. BNP Paribas Arbitrage SA raised its holdings in Harpoon Therapeutics by 310.4% in the third quarter. BNP Paribas Arbitrage SA now owns 3,755 shares of the company’s stock worth $30,000 after purchasing an additional 2,840 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in Harpoon Therapeutics during the fourth quarter worth about $34,000. 81.07% of the stock is currently owned by institutional investors and hedge funds.

Harpoon Therapeutics Company Profile (Get Rating)

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors.

Recommended Stories

Earnings History and Estimates for Harpoon Therapeutics (NASDAQ:HARP)

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.